Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

Completed · Phase 4 · Has a placebo group

Conditions studied: Muscle Spasticity, Multiple Sclerosis

In brief

The purpose of this study is to determine if Xeomin® will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.

Key facts

Study ID
NCT01968902
Run by
Multiple Sclerosis Center of Northeastern New York
People needed
27
Starts
2013-11-01
Expected to finish
2016-12-31
Last updated by the study team
2017-03-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.